---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-25-000056"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:55:23.608260+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA extends Biohaven's troriluzole PDUFA date to 4Q 2025, plans advisory committee meeting

## Summary
- FDA extends PDUFA date by 3 months to 4Q 2025 for troriluzole NDA for spinocerebellar ataxia (SCA).
- FDA plans to hold an advisory committee meeting to discuss the application; no date set.
- FDA did not raise new concerns; mid-cycle review found no major safety issues and no REMS needed.
- Troriluzole has Fast-Track, Orphan Drug, and Priority Review status; would be first approved SCA treatment.
- Clinical data showed 50-70% slowing of disease progression and reduced fall risk in SCA.

## SEC filing metadata
- accession: 0001935979-25-000056
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/0001935979-25-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000056/bhvn-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-25-000056
- JSON: https://secwatch.observer/filing/0001935979-25-000056.json
- Plain text: https://secwatch.observer/filing/0001935979-25-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.